First patient recruited for trial of new imaging modality for lung cancer

by Biotech Newsroom


LATEST NEWS: 24 February 2026

The first Australian participant has been recruited to take part in an innovative trial that could mark a shift in how radiation therapy is delivered in lung cancer.

Led by Professor Paul Keall, Director of the Image X Institute at the University of Sydney (pictured above), the USyd/TROG 21.08 VITaL (Ventilation Imaging for Thoracic Lung cancer radiation therapy) trial is investigating a novel imaging modality that could reduce radiation therapy side effects, improving quality of life for patients with…



Source link

You may also like

Houston, TX – (EmailWire) — The Biotech Times™ aggregates, publishes and distributes news about the Biotech Industry. In association with EmailWire™, The Biotech Times, helps businesses and organizations in the industry with press release distribution. Press releases are disseminated to journalists, experts, investors, trade publications and other related media outlets. For more information, contact us through the following messaging apps:

Free Magazines

Recent Articles

BioTech Times™ is part of GroupWeb Media Network. © 2026 GroupWeb Media LLC